tradingkey.logo
tradingkey.logo
Search

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study Of Mc4r Agonist Bremelanotide And Tirzepatide

ReutersApr 17, 2025 12:43 PM
facebooktwitterlinkedin

- Eli Lilly and Co LLY.N:

  • PALATIN REPORTS POSITIVE APPETITE SUPPRESSION RESULTS FROM PHASE 2 OBESITY STUDY OF MC4R AGONIST BREMELANOTIDE AND TIRZEPATIDE

  • PALATIN TECHNOLOGIES INC - ALL STUDY ARMS SHOWED IMPROVEMENT IN APPETITE SUPPRESSION

  • PALATIN TECHNOLOGIES INC - BREMELANOTIDE MATCHED OR EXCEEDED TIRZEPATIDE IN APPETITE SUPPRESSION

  • PALATIN TECHNOLOGIES INC - LOW-DOSE BREMELANOTIDE PREVENTED APPETITE REBOUND AFTER TIRZEPATIDE CESSATION

  • PALATIN TECHNOLOGIES INC - PHASE 2 TRIAL SHOWED SIGNIFICANT WEIGHT LOSS WITH BREMELANOTIDE AND TIRZEPATIDE

  • PALATIN TECHNOLOGIES INC - IND FILINGS EXPECTED BY END OF Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI